Nextar Chempharma Solutions Ltd.

Nextar Chempharma Solutions Ltd. is an Israeli biotechnology company that develops and manufactures innovative pharmaceuticals and medical devices. The company has helped bring over 180 products to market, both as a contract development and manufacturing organization (CDMO) and for its own portfolio. Nextar has manufacturing capabilities for small-scale sterile and non-sterile products, and its facilities are fully certified and some of the drug products we helped to develop are commercialized globally. Nextar is also developing a proprietary Brain-Transported Liposomes (BTLs) platform, which can deliver generic and innovative drugs across the blood-brain barrier (BBB) into the brain. This platform has the potential to revolutionize the treatment of brain diseases, such as brain cancer and Parkinson's. Nextar's first product based on the BTLs platform is currently in development for the treatment of glioblastoma. In other words, Nextar is a cutting-edge biotechnology company that is developing innovative new treatments for brain diseases. The company's BTLs platform has the potential to revolutionize the way we treat brain-related diseases.